I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

CMSC 2025

We will be contributing to topics related to
-
09:20 PM
Duration 40mins North 121 ABC
Placental and Breastmilk Transfer of Ocrelizumab From Women With Multiple Sclerosis to Infants and Potential Impact on B-Cell Levels: The MINORE and SOPRANINO Trials
Bove, Riley; Oreja-Guevara, Celia; Vukusic, Sandra; Shah, Anna; Graham, Edith L.; McElrath, Thomas; Pietrasanta, Carlo; Dobson, Ruth; Maillart, Elisabeth; Jacobs, Dina; Kletzl, Heidemarie; Kazlauskaite, Agne; Alves, Daniela; Raposo, Catarina; Craveiro, Licinio; Lin, Chien-Ju; Pasquarelli, Noemi; Hellwig, Kerstin
10:20 PM
Duration 40mins North 121 ABC
Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Results From the FENopta Open-Label Extension
Bar-Or, Amit; Oh, Jiwon; Dufek, Michal; Budincevic, Hrvoje; Habek, Mario; Caunt, Maresa; Harp, Christopher; Sierzega, Malgorzata; Clayton, David; Chen, Ying-Fang; Ratchford, John N.; Goodyear, Alexandra; Drulovic, Jelena
11:00 PM
Duration 120mins Phoenix, USA
Fatigue and Cognition Burden Among Black and African American and Hispanic and Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab for 2 Years
Williams, Mitzi; Chinea, Angel; Amezcua, Lilyana; Pandey, Krupa; Cuascut, Fernando; Goldstick, Lawrence; Hooker, Juzar; Monson, Nancy; Bernitsas, Evanthia; Reder, Anthony; Wu, Gregory; Pei, Jinglan; Abioye, Ibraheem; Vartanian, Tim
Duration 120mins Phoenix, USA
Geographic Disparities in Spatial Access to Outpatient Infusion Providers Among People With Multiple Sclerosis in the US
Pineda, Elmor D.; Majda, Thomas; Xia, Zhiyu; Wang, Rongrong
Duration 120mins Phoenix, USA
Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit–Risk Profile From the OCARINA II Study and Patient Preferences
Newsome, Scott D.; Goldstick, Lawrence; Selmaj, Krzysztof; Krzystanek, Ewa; Zecevic, Dusanka; Figueiredo, Catarina; Clinch, Susanne; Giacobino, Caroline; Azmi, Jay; Centonze, Diego
Duration 120mins Phoenix, USA
Ocrelizumab Treatment in Multiple Sclerosis: 11-Year Efficacy and Safety Clinical Trial Data
Hauser, Stephen L; Kappos, Ludwig; Weber, Martin; Nicholas, Jacqueline; Schneble, Hans-Martin; Craveiro, Licinio; Chognot, Cathy; Pasquarelli, Noemi; Wang, Qing; Bermel, Robert
Duration 120mins Phoenix, USA
MRI-Supported Relapses As a Potential Relapsing Multiple Sclerosis (RMS) Trial Outcome Measure: Use in the OPERA I and II Trials with Ocrelizumab
Alvarez, Enrique; Priest, Jessica; Hennon, Sierra; Bakdache, Fabien; Wang, Qing; Craveiro, Licincio; Krieger, Stephen
01:00 PM
Duration 15mins Phoenix Convention Center
Efficacy and Safety of a Body-Weight–Adjusted High Dose of Ocrelizumab vs the Approved Dose in Relapsing Multiple Sclerosis: Primary Results of the Phase IIIb MUSETTE Study
Hauser, Stephen; Bar-Or, Amit; Sormani, Maria Pia; Giovannoni, Gavin; Oh, Jiwon; Stoll, Sharon; Weber, Martin; Montalban, Xavier; Selmaj, Krzysztof; Maciejowski, Maciej; Nicholas, Jacqueline; Zecevic, Dusanka; Bonati, Ulrike; Wang, Qing; Schneble, Hans-Martin, Kappos, Ludwig
Coming soon